Table 4. Clinical characteristics of 17 children who failed 4 rounds of triclabendazole treatment for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru*.

Child	Community	District	Age, y/sex	Other parasites	HAZ	Living under US $3.75/day	ERR, %†	Total drug dose, mg/kg‡	Additional treatment received
1	Anta	Anta	6.8/F	Yes	−0.6	25	0§	90	1 more round
2	Anta	Anta	14.1/M	No	−2.3	25	40	90	2 more rounds
3	Conchacalla	Anta	10.5/M	No	−1.8	13	67	210	Nitazoxanide
4	Conchacalla	Anta	3.2/F	No	−2.4	36	40	50	2 more rounds
5	Conchacalla	Anta	6.0/F	No	−0.4	36	0§	210	None
6	Inquilpata	Anta	8.5/M	No	−0.9	36	30	50	2 more rounds
7	Inquilpata	Anta	9.7/F	No	−1.2	36	43	50	2 more rounds
8	Inquilpata	Anta	3.3/M	Yes	−1.2	49	+275	210	None
9	Izcuchaca	Anta	13.9/F	No	−0.6	36	+574	150	1 more round
10	Izcuchaca	Anta	7.4/M	No	−0.6	25	63	150	1 more round
11	Mantoclla	Anta	7.3/F	Yes	−2.0	25	10	150	None
12	Mantoclla	Anta	9.2/F	Yes	−1.9	25	31	150	None
13	Caccahuara	Ancahuasi	13.1/F	No	−1.5	25	17	210	Nitazoxanide
14	Caccahuara	Ancahuasi	15.5/F	No	−1.9	13	+50	210	None
15	Caccahuara	Ancahuasi	7.8/M	No	−1.1	25	+100	210	Nitazoxanide
16	Chaquillccasa	Ancahuasi	11.5/M	Yes	−0.9	25	+250	210	None
17	Chaquillccasa	Ancahuasi	5.5/F	Yes	−2.1	49	63	210	1 more round

*ERR, egg reduction rate; HAZ, height-for-age Z score. †Between baseline and after the fourth round of treatment, as estimated by the number of eggs in Kato Katz tests. + signs indicate the percent increase in the egg count. ‡Total cumulative dose received after the fourth round of treatment §Diagnosed only by Lumbreras rapid sedimentation test and a negative Kato Katz test result.